Stay updated with breaking news from Roche Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BNT211 combines two innovative approaches in one regimen with first-in-class potential: an autologous CAR-T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) and a CLDN6-encoding CAR-T cell amplifying RNA
BNT211 combines two innovative approaches in one regimen with first-in-class potential: an autologous CAR-T cell therapy targeting the oncofetal antigen Claudin-6 and a CLDN6-encoding CAR-T cell...
:max_bytes(150000):strip_icc()/GettyImages-1365908035-7aabb794cb0f413da9cd46ebbac2f2ec.jpg)
Roivant agreed to sell its Telavant joint venture with Pfizer to Roche for $7.1 billion.
VANCOUVER – USA News Group – A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent individuals and institutions such as MIT, Memorial Sloan Kettering Cancer Center and The ...
Chugai's Alecensa Reduces the Risk of Disease Recurrence or Death by 76% in People with ALK-PositiveEarly-StageNon-Small Cell Lung Cancer ...